Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Edgeline Holdings has agreed to terms for an exclusive worldwide right to option patents covering the composition and use of Genistein analogs for cancer treatment.
Subscribe to our email newsletter
The technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw, Poland and involves compounds that appear to be novel antimicrotubule agents.
Donald Picker, COO of Edgeline Holdings, said: “We are very excited to have the opportunity to develop what may be yet another unique antimicrotubule class of compounds. This specific mechanism continues to be of great interest to the cancer research community as it may provide yet another different spectrum of activity in the clinic.”